Li Yue, Yang Qing, Chen Minhua, Cai Heng, Fang Li, Zhou Junxin, Weng Rui, Ni Hanming, Jiang Yan, Hua Xiaoting, Yu Yunsong
Department of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Regional Medical Center for National Institute of Respiratory Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Commun Biol. 2024 Dec 19;7(1):1646. doi: 10.1038/s42003-024-07337-5.
Klebsiella pneumoniae carbapenemase-producing Pseudomonas aeruginosa (KPC-PA) isolates have quickly expanded in China, especially the high-risk clone ST463. We aimed to explore the evolution of KPC-related plasmids driving ST463 clone success. Whole-genome sequencing of 1258 clinical P. aeruginosa strains (2011-2020) identified 106 ST463-PA isolates, with a KPC prevalence of 90.6%. Early on (2011-2012), ST463-PA obtained the KPC-encoding type II (pT2-KPC) or type I plasmid (pT1-KPC) to overcome carbapenem stress. Between 2012 and 2017, pT1-KPC plasmid dominated due to its lower fitness costs and IS26-driven bla amplification ability. By 2017-2020, large fragment deletions in pT1-KPC formed pT1-KPC plasmid. It conferred even lower fitness costs, enhanced bla gene stability, and greater copy-number flexibility, while maintaining horizontal transmission ability. Consequently, pT1-KPC plasmid finally succeeded, making ST463 the dominant ST in China. Our findings highlight evolutionary pressures driving ST463 dominance and emphasize the need for targeted strategies to control its spread and antibiotic resistance development.
产肺炎克雷伯菌碳青霉烯酶的铜绿假单胞菌(KPC-PA)分离株在中国迅速增多,尤其是高危克隆株ST463。我们旨在探究驱动ST463克隆株成功的KPC相关质粒的进化情况。对1258株临床铜绿假单胞菌菌株(2011 - 2020年)进行全基因组测序,鉴定出106株ST463-PA分离株,KPC流行率为90.6%。早期(2011 - 2012年),ST463-PA获得了编码KPC的II型质粒(pT2-KPC)或I型质粒(pT1-KPC)以克服碳青霉烯类抗生素压力。在2012年至2017年间,pT1-KPC质粒因较低的适应性代价和由IS26驱动的bla扩增能力而占据主导。到2017 - 2020年,pT1-KPC中的大片段缺失形成了pT1-KPC质粒。它赋予了更低的适应性代价、增强了bla基因稳定性以及更大的拷贝数灵活性,同时保持了水平传播能力。因此,pT1-KPC质粒最终成功,使ST463成为中国的优势序列型。我们的研究结果突出了驱动ST463占主导地位的进化压力,并强调需要采取针对性策略来控制其传播和抗生素耐药性发展。